Bicycle Therapeutics (NASDAQ:BCYC) COO Alistair Milnes Sells 3,244 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) COO Alistair Milnes sold 3,244 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $6.80, for a total transaction of $22,059.20. Following the transaction, the chief operating officer owned 140,133 shares of the company’s stock, valued at approximately $952,904.40. This trade represents a 2.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Alistair Milnes also recently made the following trade(s):

• On Monday, January 5th, Alistair Milnes sold 3,416 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total transaction of $22,067.36.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ:BCYC opened at $6.57 on Wednesday. The stock has a market capitalization of $455.76 million, a price-to-earnings ratio of -1.81 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a 1-year low of $6.03 and a 1-year high of $15.47. The company has a 50 day moving average price of $6.97 and a 200 day moving average price of $7.42.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.24. The company had revenue of $11.73 million for the quarter, compared to analysts’ expectations of $8.25 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%. On average, sell-side analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

Key Bicycle Therapeutics News

Here are the key news stories impacting Bicycle Therapeutics this week:

• Negative Sentiment: CEO Kevin Lee sold a total of 21,314 shares across trades on Jan. 2 and Jan. 5 (average prices ~$6.80 and ~$6.46), reducing his stake by roughly 1.6–1.7%; he still holds ~619k shares. SEC Form 4 — Kevin Lee
• Negative Sentiment: CFO Alethia Young sold 7,623 shares across Jan. 2 and Jan. 5 trades (avg prices ~$6.80 and ~$6.49), cutting her position by ~3.5–4.7%; she retains ~87k shares. SEC Form 4 — Alethia Young
• Negative Sentiment: COO Alistair Milnes sold 6,660 shares across the two dates (avg prices ~$6.80 and ~$6.46), a ~2.3–2.4% reduction; he still holds ~137k–140k shares. SEC Form 4 — Alistair Milnes
• Negative Sentiment: CAO Travis Alvin Thompson sold 2,432 shares across Jan. 2 and Jan. 5 (avg prices ~$6.80 and ~$6.45), trimming his stake by ~1.6–1.9%; he remains a meaningful holder. SEC Form 4 — Travis Alvin Thompson

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC grew its position in Bicycle Therapeutics by 6.4% during the third quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock valued at $23,050,000 after purchasing an additional 178,000 shares in the last quarter. Long Focus Capital Management LLC boosted its stake in shares of Bicycle Therapeutics by 7.7% during the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after buying an additional 101,402 shares during the period. Moore Capital Management LP grew its holdings in shares of Bicycle Therapeutics by 66.7% during the 3rd quarter. Moore Capital Management LP now owns 125,000 shares of the company’s stock valued at $968,000 after acquiring an additional 50,000 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of Bicycle Therapeutics by 20.3% in the third quarter. Citadel Advisors LLC now owns 189,027 shares of the company’s stock worth $1,463,000 after acquiring an additional 31,860 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Bicycle Therapeutics by 21.7% during the third quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after acquiring an additional 2,668 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BCYC. Citizens Jmp lifted their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Friday, October 31st. Truist Financial assumed coverage on shares of Bicycle Therapeutics in a report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price for the company. Citigroup reissued an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Royal Bank Of Canada restated a “sector perform” rating and issued a $11.00 price target (down previously from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.73.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.